N/A
N=24,465
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Diabetes Mellitus, Type 2
Bottom Line
View on ClinicalTrials.gov: NCT04295005 ↗Enrolled (actual)
24,465
Serious AEs
—
Results posted
Aug 2024
Primary outcome: Primary: Direct Healthcare Cost — 4247; 7009; 4319; 6535 Euro / patient-year — p=< 0.001
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Empagliflozin (Drug); DPP-4i (Drug); GLP-1-RA (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Boehringer Ingelheim
- Primary completion
- Sep 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Direct Healthcare Cost |
4247; 7009; 4319; 6535; 4895; 6851 | < 0.001 sig |
| PRIMARY Healthcare Resource Utilization |
— | — |
| SECONDARY Indirect Healthcare Costs (Including Indirect Costs of Days Absent From Work) |
— | — |
Summary
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
Eligibility Criteria
Inclusion Criteria
- Continuous insurance by the sickness fund for the entire period (01/01/2014 - 31/12/2018; death of a patient is the only accepted exception from this rule)
- At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at least one inpatient T2DM diagnosis (ICD E11.-) in the period 01/01/2014 to 31/12/2016, but before or on index date (i.e. first Empagliflozin or DPP-4i /Sitagliptin prescription).
- At least one prescription of Empagliflozin or a DPP-4i /Sitagliptin in the inclusion period (01/01/2015 - 31/12/2016)
Exclusion Criteria
- At least one prescription of a sodium glucose transporter 2 inhibitor (SGLT-2i), DPP-4i or GLP-1-RA in the baseline period (01/01/2014 - 31/12/2014)
- During follow-up, patients will be censored if they switch to any SGLT-2i, DPP-4i or GLP-1-RA or initiate a concomitant use of any SGLT-2i, DPP-4i or GLP-1-RA (free or fixed-dose combinations).
Data sourced from ClinicalTrials.gov (NCT04295005). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.